Back to mobile site

Incyte (INCY) Tops Q3 EPS by 46c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. ALAR
3. SPY
4. PBA
5. CCH:LN
6. META
7. CCHGY
8. PRY:IM
9. PRYMY
10. SKA-B

November 2, 2021 7:16 AM EDT

Incyte (NASDAQ: INCY) reported Q3 EPS of $1.18, $0.46 better than the analyst estimate of $0.72. Revenue for the quarter came in at $813 million versus the consensus estimate of $738.52 million.

2021 Financial Guidance:

The Company has reaffirmed its full year 2021 financial guidance, as detailed below. Guidance does not include revenue from Opzelura in the U.S., Minjuvi in Europe or the impact of any potential future strategic transactions.

Current

Previous

Jakafi net product revenues

$2,125 - $2,170 million

Unchanged

Other Hematology/Oncology net product revenues

$155 - $170 million

Unchanged

GAAP Cost of product revenues

6 – 7% of net product revenues

Unchanged

Non-GAAP Cost of product revenues1

5 – 6% of net product revenues

Unchanged

GAAP Research and development expenses

$1,350 - $1,390 million

Unchanged

Non-GAAP Research and development expenses2

$1,220 - $1,250 million

Unchanged

GAAP Selling, general and administrative expenses

$725 - $755 million

Unchanged

Non-GAAP Selling, general and administrative expenses3

$655 - $680 million

Unchanged

1 Adjusted to exclude the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated cost of stock-based compensation.
2 Adjusted to exclude the estimated cost of stock-based compensation.
3 Adjusted to exclude the estimated cost of stock-based compensation and legal settlements.

For earnings history and earnings-related data on Incyte (INCY) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings, Guidance

Related Entities

Earnings, Definitive Agreement